Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068663 | 0.88 | CA12 (0.52) | MAOAKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL7072951 | 0.87 | MAOB (0.45) | MAOAALOX15KDM4ENPC1RAB9A | |
| SCHEMBL7184162 | 0.85 | MAOA (0.52) | MAOAKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL7067921 | 0.83 | NQO1 (0.49) | MAOAKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL7070727 | 0.81 | ALOX5 (0.53) | MAOAKDM4EALDH1A1LMNA | |
| SCHEMBL7067916 | 0.80 | KDM4E (0.46) | MAOAKDM4EALDH1A1LMNACA9 | |
| SCHEMBL3326973 | 0.76 | ALOX15 (0.50) | MAOAALOX15KDM4EALDH1A1LMNA | |
| SCHEMBL6901789 | 0.76 | KDM4E (0.74) | KDM4EALDH1A1LMNA | |
| SCHEMBL7070719 | 0.73 | CA12 (0.46) | MAOAKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL9836804 | 0.72 | MAOA (0.56) | MAOAKDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620842-B2 | Chalcones | INDENA SPA (IT) | 2003-09-16 | — | — | US | disclosed |
| EP-1212315-B1 | NOVEL CHALCONES | INDENA SPA (IT) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | INDENA S.P.A. (IT) | 2003-03-20 | — | — | US | disclosed |
| EP-1212315-A1 | NOVEL CHALCONES | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017988-A1 | NOVEL CHALCONES | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | HDGF, MKI67, HPD | MAOA 3276/4885ALOX15 2128/4885KDM4E 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.